KITLG抗体;KITLG Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using KITLG mouse mAb (green) and negative control (red).    

  
  

**Background of KITLG Antibody**

The KIT ligand (KITLG), also known as stem cell factor (SCF) or steel factor, is a cytokine critical for cellular signaling via its receptor c-KIT, a tyrosine kinase. It plays essential roles in hematopoiesis, germ cell development, melanogenesis, and mast cell regulation by activating downstream pathways like PI3K/AKT and MAPK/ERK, which govern survival, proliferation, and differentiation. Dysregulation of KITLG/c-KIT signaling is linked to cancers (e.g., gastrointestinal stromal tumors, leukemia), inflammation, and infertility.

KITLG antibodies are tools or therapeutics designed to target this pathway. In research, they block KITLG-c-KIT interactions to study physiological/pathological mechanisms. Therapeutically, monoclonal antibodies (mAbs) inhibit aberrant c-KIT signaling in cancers, suppressing tumor growth. They also show potential in managing allergies and autoimmune disorders by modulating mast cell activity. Polyclonal antibodies are often used in diagnostics to detect KITLG expression levels, aiding disease biomarker studies. Challenges include minimizing off-target effects and overcoming drug resistance. Ongoing research focuses on optimizing antibody specificity and efficacy for clinical applications.